Efficacy of empagliflozin for weight and glycemic control of a patient with Prader-Willi syndrome, systemic lymphedema and extreme obesity: a case report-Reference-Cited by-同舟云学术

Efficacy of empagliflozin for weight and glycemic control of a patient with Prader-Willi syndrome, systemic lymphedema and extreme obesity: a case report

Published:2022-04-27 Issue:4 Volume:42 Page:787-790
ISSN:0973-3930
Container-title:International Journal of Diabetes in Developing Countries
language:en
Short-container-title:Int J Diabetes Dev Ctries

Author:

Farinha Juliano Boufleur^ORCID,Weinert Letícia Schwerz,Costa Lidiane Pozza,Costa Marcelo Zanusso,de Peres Patrícia Peres,Lorea Cláudia Fernandes

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://link.springer.com/content/pdf/10.1007/s13410-022-01076-1.pdf

Reference10 articles.

1. Heitink MV, Sinnema M, van Steensel MAM, Schrander-Stumpel CTRM, Frank J, Curfs LMG. Lymphedema in Prader-Willi syndrome. Int J Dermatol. 2008;47(1):42–4. https://doi.org/10.1111/j.1365-4632.2008.03959.x.

2. Manzardo AM, Heinemann J, McManus B, Loker C, Loker J, Butler MG. Venous Thromboembolism in Prader-Willi Syndrome: a questionnaire survey. Genes (Basel). 2019;10(7). https://doi.org/10.3390/genes10070550.

3. Sano H, Kudo E, Yamazaki T, Ito T, Hatakeyama K, Kawamura N. Efficacy of sodium-glucose cotransporter 2 inhibitor with glucagon-like peptide-1 receptor agonist for the glycemic control of a patient with Prader-Willi syndrome: a case report. Clin Pediatr Endocrinol. 2020;29(2):81–4. https://doi.org/10.1297/cpe.29.81.

4. Morales JS, Valenzuela PL, Pareja-Galeano H, Rincón-Castanedo C, Rubin DA, Lucia A. Physical exercise and Prader-Willi syndrome: a systematic review. Clin Endocrinol (Oxf). 2019;90(5):649–61. https://doi.org/10.1111/cen.13953.

5. Grada AA, Phillips TJ. Lymphedema: pathophysiology and clinical manifestations. J Am Acad Dermatol. 2017;77(6):1009–20. https://doi.org/10.1016/j.jaad.2017.03.022.